DirectorsTalk – Q&A with Professor Steve Myers at Advanced Oncotherapy (AVO).

Advanced Oncotherapy PLC (LON:AVO) subsidiary ADAM S.A. Executive Chairman professor Steve Myers talks to DirectorsTalk about the LIGHT system, it’s likely impact, the design, the progress being made and its future. Q1: Professor Myers, you became Executive Chairman of ADAM S.A. (ADAM), the CERN spin-off and Advanced Oncotherapy’s (AVO’s) subsidiary, in late 2015, and joined AVO’s […]

Advanced Oncotherapy (AVO) – Non-exec Professor Steve Myers buys 400,000 shares at 26p.

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers, Non-Executive Director of the Company, has purchased today a total of 400,000 ordinary shares of 25 pence in the Company at a price of 26 pence per Ordinary Share. Following this transaction, Professor Myers holds 450,569 Ordinary […]

Advanced Oncotherapy (AVO) – Appointment of Non-Executive Directors

  Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Professor Steve Myers OBE and Mr Hans von Celsing as Non-Executive Directors with immediate effect. In addition, Mr von Celsing will become Senior Independent Non-Executive Director. Professor Myers’ appointment follows the announcement of the Company’s intention to […]

Advanced Oncotherapy (AVO) – Further progress in the technical development of the LIGHT system

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has integrated the proton source and Radio Frequency Quadruple (RFQ), following a successful testing and calibration programme at ADAM, in Geneva. This work has demonstrated there is a predicted acceleration of the proton beam through this very […]

Advanced Oncotherapy (AVO) – Directorate Change

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Lord David Evans has stepped down from the Board with immediate effect. In addition, the board of directors of Advanced Oncotherapy intends to appoint Professor Stephen Myers as member of the Board. A further announcement in relation to the […]